1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
2. Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21–1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34(6):3205–10.
3. Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, et al. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354.
4. Liang ZK, Yin YJ, Wu ED, Shi GL. The clinical value of new tumor biomarker cytokeratin 2G2 detection in non-small cell lung cancer patients. Clin Lab. 2013;59(5–6):551–6.
5. Gao J, Lv F, Li J, Wu Z, Qi J. Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer. PLoS One. 2014;9(7), e101979.